Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...
Mother Daphne Graskewicz-Prado of Southern Illinois told Newsweek: “I wasn’t going to accept the terminal diagnosis.” ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
DURHAM, N.C. (WTVD) -- Duke Eye Center has become the first academic medical center in the country to implant a new ...
After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...
Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in | Just as Adverum’s cash reserves ...
The U.S. Food and Drug Administration has placed a clinical hold on Intellia Therapeutics' two late-stage trials testing an ...
Cleveland Clinic Children’s researchers have uncovered a genetic link to osteosarcoma, the most common bone cancer in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback